

12 August 2021

ASX Code: MXC

LSE Code: MXC

Results of General Meeting

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the company's General Meeting held today, 12 August 2021, in accordance with Listing Rule 3.13.2.

Please note that the resolutions put to the meeting were voted by poll, will all resolutions carried by a clear majority.

Details of the proxy voting and voting outcomes for each resolution put to the meeting are set out in the attached report.

--Ends--

Authorised for release by the Chairman, for further information please contact:
MGC Pharmaceuticals Ltd

Roby Zomer
 CEO & Managing Director
 +61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope

Andy Thacker
 +44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd

David Lim
 Company Secretary
 +61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock

Tim Pearson
 +44 207 920 3150
Tim.Pearson@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



MGC Pharmaceuticals Ltd
General Meeting
Thursday, 12 August 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1 Ratification of Prior Issue of Shares – Part Consideration for the Acquisition of MediCaNL	Ordinary	397,917,190 97.97%	3,742,938 0.92%	4,479,219 1.11%	7,574,955	408,768,455 99.09%	3,742,938 0.91%	7,574,955	Carried	
2 Approval to issue Deferred Consideration Shares for Acquisition of MediCaNL	Ordinary	397,183,151 97.77%	4,470,034 1.10%	4,559,310 1.13%	7,501,807	408,114,507 98.92%	4,470,034 1.08%	7,501,807	Carried	
3 Issue of Performance Rights to Roby Zomer	Ordinary	309,935,730 83.53%	56,527,481 15.24%	4,577,910 1.23%	42,673,181	314,555,640 84.77%	56,527,481 15.23%	49,003,227	Carried	
4 Issue of Performance Rights to Brett Mitchell	Ordinary	309,943,430 83.55%	56,421,781 15.22%	4,567,910 1.23%	42,781,181	314,553,340 84.79%	56,421,781 15.21%	49,111,227	Carried	
5 Issue of Performance Rights to Nativ Segev	Ordinary	309,767,817 83.37%	56,537,481 15.22%	5,240,780 1.41%	42,168,224	315,050,597 84.78%	56,537,481 15.22%	48,498,270	Carried	
6 Issue of Performance Rights to Stephen Parker	Ordinary	310,369,630 83.55%	56,461,781 15.20%	4,639,580 1.25%	42,243,311	315,051,210 84.80%	56,461,781 15.20%	48,573,357	Carried	
7 Issue of Performance Rights to Ross Walker	Ordinary	310,470,600 83.57%	56,444,481 15.20%	4,567,910 1.23%	42,231,311	315,080,510 84.81%	56,444,481 15.19%	48,561,357	Carried	
8 Issue of Performance Rights to Evan Hayes	Ordinary	305,898,430 82.45%	56,521,781 15.24%	8,567,910 2.31%	42,726,181	314,508,340 84.77%	56,521,781 15.23%	49,056,227	Carried	
9 Ratification of Prior Issue of Shares to Cannvalate Pty Ltd	Ordinary	366,522,029 95.38%	13,175,078 3.43%	4,567,910 1.19%	5,297,764	377,461,985 96.63%	13,175,078 3.37%	5,297,764	Carried	

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.